Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2023; 18(03): 602-608
DOI: 10.1055/s-0043-1774821
Original Article

Retrospective Evaluation of Cases Undergoing Stereotaxic Brain Biopsy

Abdullah Yolcu 
1   Department of Neurosurgery, Haydarpaşa Numune Training and Research Hospital, Istanbul, Türkiye
,
Ezgi Akar 
1   Department of Neurosurgery, Haydarpaşa Numune Training and Research Hospital, Istanbul, Türkiye
,
Fügen Vardar Aker 
2   Department of Pathology, Haydarpaşa Numune Training and Research Hospital, İstanbul, Türkiye
,
Selin Tural Emon 
1   Department of Neurosurgery, Haydarpaşa Numune Training and Research Hospital, Istanbul, Türkiye
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective: The aim of this study is to evaluate the demographic, radiological and histopathological findings, tumoral biomarkers, and survival rates of patients who underwent a stereotactic brain biopsy and those diagnosed with glioblastoma, metastasis, and lymphoma, and the changes in the diagnosis distribution over the years.

Materials and Methods: The patients who underwent stereotactic biopsy in our clinic between 2012 and 2020 were evaluated retrospectively. Metastasis, glioblastoma, and lymphoma cases were evaluated as three main groups and the others were excluded. P53 gene expression, isocitrate dehydrogenase (IDH) mutation, and Ki-67 values in glioblastoma cases and Bcl-2, Bcl-6 proteins, and Ki-67 values in lymphomas and their relationship with survival were evaluated.

Results: High p53 expression was observed in 27.5% cases diagnosed with glioblastoma. IDH mutation was negative in all glioblastoma cases. Presence of Bcl-2 and Bcl-6 proteins was not associated with survival in lymphomas. Survival rate was significantly higher in cases diagnosed with lymphoma (26.9%) compared to those diagnosed with glioblastoma. A statistically significant increase was determined in patients diagnosed with lymphoma considering the distribution of diseases and incidence and in the distribution of other diagnoses over the years (p < 0.05).

Conclusion: As per the distribution of the disease in recent times, it has been observed that there is an increase in lymphoma cases. Histopathology and biomarkers have great importance in the diagnosis and treatment of cerebral lesions. We think that our findings will be supported by studies in which larger patient population and detailed biomarkers will be studied.

Keywords

stereotactic brain biopsy - primary central nervous system lymphomas - glioblastoma - cerebral metastasis

Statement of Ethics

Study approval statement:


Our study was approved by the local ethics committee with the decision number HNEAH-KAEK 2021/228 dated 20.09.2021.


Authors' Contributions

Abdullah Yolcu was involved in the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work


Ezgi Akar drafted the work. Fügen Vardar Aker agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Selin Tural Emon provided final approval.




Publication History

Article published online:
27 September 2023

© 2023. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kim JE, Kim DG, Paek SH, Jung HW. Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning of treatment. Acta Neurochir (Wien) 2003; 145 (07) 547-554 , discussion 554–555
    CrossrefPubMedSearch in Google Scholar
  • 2 Kreth FW, Muacevic A, Medele R, Bise K, Meyer T, Reulen HJ. The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours–a prospective study. Acta Neurochir (Wien) 2001; 143 (06) 539-545 , discussion 545–546
    CrossrefPubMedSearch in Google Scholar
  • 3 Ersahin M, Karaaslan N, Gurbuz MS. et al. The safety and diagnostic value of frame-based and CT-guided stereotactic brain biopsy technique. Turk Neurosurg 2011; 21 (04) 582-590
    PubMedSearch in Google Scholar
  • 4 Silva EU, Vasconcellos LP, Lara Jr NA, Veiga JC, Lancellotti CL, Shiozawa P. Stereotactic biopsy for intracranial lesions: clinical-pathological compatibility in 60 patients. Arq Neuropsiquiatr 2009; 67 (04) 1062-1065
    CrossrefPubMedSearch in Google Scholar
  • 5 Chen CC, Hsu PW, Erich Wu TW. et al. Stereotactic brain biopsy: single center retrospective analysis of complications. Clin Neurol Neurosurg 2009; 111 (10) 835-839
    CrossrefPubMedSearch in Google Scholar
  • 6 Haldorsen IS, Kråkenes J, Krossnes BK, Mella O, Espeland A. CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. AJNR Am J Neuroradiol 2009; 30 (04) 744-751
    CrossrefPubMedSearch in Google Scholar
  • 7 Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996; 27 (01) 65-73
    CrossrefPubMedSearch in Google Scholar
  • 8 Zagzag D, Goldenberg M, Brem S. Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. AJR Am J Roentgenol 1989; 153 (01) 141-146
    CrossrefPubMedSearch in Google Scholar
  • 9 Carapella CM, Oppido PA. Present role of surgery for brain metastases. World Neurosurg 2018; 120: 423-425
    CrossrefPubMedSearch in Google Scholar
  • 10 Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44 (03) 275-281
    CrossrefPubMedSearch in Google Scholar
  • 11 Corn BW, Marcus SM, Topham A, Hauck W, Curran Jr WJ. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?. Cancer 1997; 79 (12) 2409-2413
    CrossrefPubMedSearch in Google Scholar
  • 12 Achrol AS, Rennert RC, Anders C. et al. Brain metastases. Nat Rev Dis Primers 2019; 5 (01) 5
    CrossrefPubMedSearch in Google Scholar
  • 13 Go JL, Lee SC, Kim PE. Imaging of primary central nervous system lymphoma. Neurosurg Focus 2006; 21 (05) E4
    PubMedSearch in Google Scholar
  • 14 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131 (06) 803-820
    CrossrefPubMedSearch in Google Scholar
  • 15 Ohgaki H, Burger P, Kleihues P. Definition of primary and secondary glioblastoma–response. Clin Cancer Res 2014; 20 (07) 2013
    CrossrefPubMedSearch in Google Scholar
  • 16 Stoyanov GS, Dzhenkov DL, Kitanova M, Donev IS, Ghenev P. Correlation Between Ki-67 Index, World Health Organization Grade and Patient Survival in Glial Tumors With Astrocytic Differentiation. Cureus 2017; 9 (06) e1396
    PubMedSearch in Google Scholar
  • 17 Ghosh M, Shubham S, Mandal K, Trivedi V, Chauhan R, Naseera S. Survival and prognostic factors for glioblastoma multiforme: retrospective single-institutional study. Indian J Cancer 2017; 54 (01) 362-367
    CrossrefPubMedSearch in Google Scholar
  • 18 Moskowitz SI, Jin T, Prayson RA. Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 2006; 76 (02) 193-200
    CrossrefPubMedSearch in Google Scholar
  • 19 Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6 (03) 217-223 , discussion 23–24
    CrossrefPubMedSearch in Google Scholar
  • 20 Newcomb EW, Cohen H, Lee SR. et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 1998; 8 (04) 655-667
    CrossrefPubMedSearch in Google Scholar
  • 21 Birner P, Piribauer M, Fischer I. et al. Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 2002; 9 (04) 703-707
    PubMedSearch in Google Scholar
  • 22 Malkoun N, Chargari C, Forest F. et al. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol 2012; 106 (01) 127-133
    CrossrefPubMedSearch in Google Scholar
  • 23 Tun HW, Personett D, Baskerville KA. et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111 (06) 3200-3210
    CrossrefPubMedSearch in Google Scholar
  • 24 Yang XL, Liu YB. Advances in pathobiology of primary central nervous system lymphoma. Chin Med J (Engl) 2017; 130 (16) 1973-1979
    CrossrefPubMedSearch in Google Scholar
  • 25 Altman DA, Atkinson Jr DS, Brat DJ. Best cases from the AFIP: glioblastoma multiforme. Radiographics 2007; 27 (03) 883-888
    CrossrefPubMedSearch in Google Scholar
  • 26 Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988; 68 (06) 835-853
    CrossrefPubMedSearch in Google Scholar
  • 27 Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus 2006; 21 (05) E1
    CrossrefPubMedSearch in Google Scholar
  • 28 Nabavizadeh SA, Vossough A, Hajmomenian M, Assadsangabi R, Mohan S. Neuroimaging in central nervous system lymphoma. Hematol Oncol Clin North Am 2016; 30 (04) 799-821
    CrossrefPubMedSearch in Google Scholar
  • 29 Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70 (02) 510-514
    CrossrefPubMedSearch in Google Scholar
  • 30 Gaspar L, Scott C, Rotman M. et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37 (04) 745-751
    CrossrefPubMedSearch in Google Scholar